Cross‐ancestry polygenic risk scores enhance Alzheimer’s disease risk prediction in multiethnic cohorts

by Clinical Neuropsychologist Online | Tuesday, July 28, 2026 | Dementia

Abstract INTRODUCTION Genome-wide association studies (GWAS) have identified 80+ genetic loci associated with Alzheimer’s disease (AD), enabling the development of polygenic risk scores (PRS). However, the predictive accuracy of PRS in diverse populations...

Reproductive neuroendocrine pathways as modulators of sleep‐related sex differences in Alzheimer’s disease

by Clinical Neuropsychologist Online | Tuesday, July 28, 2026 | Dementia

Alzheimer’s &Dementia, Volume 22, Issue 8, August 2026. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | July 28, 2026 Neuro-Dementia Previous...

Designing Engagement in Dementia Care: Embodied Participation, Situated Adaptation, and Co-Design-In-Practice

by Clinical Neuropsychologist Online | Tuesday, July 28, 2026 | Dementia

Dementia, Ahead of Print. This study explores how a tactile and play-based intervention, the Colorful Counting Brickers, fostered emotional and social engagement among older adults with dementia in a Taiwanese long-term care setting informed by relationally grounded...

Recent Cochrane review has serious flaws: A perspective of clinicians and researchers from around the world

by Clinical Neuropsychologist Online | Tuesday, July 28, 2026 | Dementia

Abstract In response to a Cochrane review (published in April 2026) on the clinical trials of monoclonal antibodies targeting beta amyloid, this perspective outlines a number of critiques. The scientists, methodologists, subject-matter experts, and clinicians on this...

Analytical framing of Amyloid beta monoclonal antibody trials in Alzheimer’s disease can obscure clinical effects

by Clinical Neuropsychologist Online | Tuesday, July 28, 2026 | Dementia

Abstract Cochrane Reviews are widely regarded as the gold standard for evidence synthesis, yet analytical framing influences interpretation. A recent Cochrane review of amyloid beta–targeting monoclonal antibodies pools mechanistically and biologically heterogenous...

CONNECT4 APOE: A randomized trial of telephone versus real‐time two‐way videoconference for disclosure of APOE genotype results in cognitively unimpaired adults

by Clinical Neuropsychologist Online | Tuesday, July 28, 2026 | Dementia

Abstract INTRODUCTION Data are needed to inform best practices for disclosing apolipoprotein E (APOE) results given increasing indications for testing. METHODS CONNECT4, a multi-center, randomized trial (NCT02978729) compared disclosure of APOE genotype by...